BEIJING, Sept. 25 (Xinhua) -- Two inactivated COVID-19 vaccines developed by the China National Biotec Group (CNBG) are under phase-3 clinical trials in the Middle East, with more than 35,000 people inoculated, according to an official with the Ministry of Science and Technology (MOST).
Wu Yuanbin, director-general of science and technology for social development with the MOST, said during a press conference in Beijing on Friday that Chinese vaccine production enterprises signed cooperative agreements with institutions from a number of countries to jointly implement phase-3 clinical trials in accordance with the laws and regulations.